Jackson Hole Capital Partners LLC Trims Holdings in Zoetis Inc. (NYSE:ZTS)

Jackson Hole Capital Partners LLC decreased its holdings in Zoetis Inc. (NYSE:ZTS) by 10.4% in the 4th quarter, Holdings Channel reports. The firm owned 18,717 shares of the company’s stock after selling 2,168 shares during the period. Jackson Hole Capital Partners LLC’s holdings in Zoetis were worth $3,050,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Darwin Wealth Management LLC purchased a new stake in Zoetis in the 3rd quarter valued at $31,000. First Personal Financial Services purchased a new stake in Zoetis in the 3rd quarter valued at $33,000. Capital Performance Advisors LLP purchased a new stake in Zoetis in the 3rd quarter valued at $33,000. Dunhill Financial LLC raised its position in Zoetis by 80.6% in the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock valued at $33,000 after purchasing an additional 75 shares during the last quarter. Finally, Atlantic Edge Private Wealth Management LLC raised its position in Zoetis by 482.8% in the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock valued at $28,000 after purchasing an additional 140 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have commented on ZTS shares. UBS Group started coverage on shares of Zoetis in a research report on Monday, December 9th. They set a “neutral” rating and a $196.00 price objective for the company. Morgan Stanley cut their price objective on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a research report on Friday, February 14th. Stifel Nicolaus cut their price objective on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. Barclays upped their price objective on shares of Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a research report on Friday, February 14th. Finally, Leerink Partners started coverage on shares of Zoetis in a research report on Monday, December 2nd. They set an “outperform” rating and a $215.00 price objective for the company. One analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Zoetis currently has an average rating of “Buy” and an average target price of $215.90.

Insider Transactions at Zoetis

In other news, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total transaction of $55,804.68. Following the completion of the sale, the executive vice president now directly owns 16,107 shares in the company, valued at $2,757,196.26. The trade was a 1.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 0.16% of the company’s stock.

Zoetis Stock Performance

NYSE:ZTS opened at $170.34 on Friday. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09. The firm has a 50-day moving average price of $166.72 and a two-hundred day moving average price of $176.78. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $200.33. The company has a market capitalization of $76.28 billion, a P/E ratio of 31.14, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, beating the consensus estimate of $1.37 by $0.03. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The firm had revenue of $2.32 billion during the quarter, compared to the consensus estimate of $2.30 billion. As a group, research analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be issued a dividend of $0.50 per share. The ex-dividend date is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.17%. Zoetis’s dividend payout ratio (DPR) is presently 36.56%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.